TY - JOUR
T1 - Infections in children with down syndrome and acute myeloid leukemia
T2 - A report from the Canadian infections in AML research group
AU - Tran, Thai Hoa
AU - Mitchell, David
AU - Dix, David
AU - Cellot, Sonia
AU - Ethier, Marie Chantal
AU - Gillmeister, Biljana
AU - Hitzler, Johann
AU - Lewis, Victor
AU - Yanofsky, Rochelle
AU - Johnston, Donna L.
AU - Portwine, Carol
AU - Price, Victoria
AU - Zelcer, Shayna
AU - Silva, Mariana
AU - Michon, Bruno
AU - Bowes, Lynette
AU - Stobart, Kent
AU - Brossard, Josee
AU - Beyene, Joseph
AU - Sung, Lillian
N1 - Funding Information:
This work was supported by a grant from the Canadian Cancer Society (Grant #019468) and the C17 Research Network. LS is supported by a New Investigator Award from the Canadian Institutes of Health Research.
PY - 2013/12/2
Y1 - 2013/12/2
N2 - Background: Children with Down syndrome (DS) are at high risk of infectious toxicity when treated with acute lymphoblastic leukemia chemotherapy protocols optimized in children without DS. Our objective was to determine if children with DS and acute myeloid leukemia (AML) have a different risk of infection when treated with chemotherapy protocols developed for children with DS compared to AML treatment protocols developed for children without DS. Methods. We conducted a retrospective, population-based cohort study that included DS children ≤ 18 years of age with de novo, non-M3 AML diagnosed between January 1995 and December 2004, and treated at 15 Canadian centers. Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle of chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease or death (whichever occurred first). Trained research associates abstracted all information from each site. Results: There were 31 children with DS included; median age was 1.7 (range 0.1-11.1) years. Eleven were treated according to a DS-specific protocol while 20 were treated with non-DS specific protocols. A total of 157 courses of chemotherapy were delivered. Microbiologically documented sterile site infection occurred in 11.9% and 14.3% of DS-specific and non-DS specific AML treatment courses respectively. Sepsis was rare and there were no infection-related deaths. In multiple regression, treatment with a DS-specific protocol was independently associated with a reduction in microbiologically documented sterile site infection (adjusted odds ratio (OR) 0.65, 95% confidence interval (CI) 0.42-0.99; P = 0.044), and clinically documented infection (adjusted OR 0.36, 95% CI 0.14-0.91; P = 0.031) but not bacteremia (adjusted OR 0.73, 95% CI 0.44-1.22; P = 0.231). Conclusions: Our study suggests that children with DS do not experience excessive infectious toxicity during treatment for AML compared to children without DS. Incorporation of DS-specific AML treatment protocols is associated with a more favorable infection profile for children with DS-AML.
AB - Background: Children with Down syndrome (DS) are at high risk of infectious toxicity when treated with acute lymphoblastic leukemia chemotherapy protocols optimized in children without DS. Our objective was to determine if children with DS and acute myeloid leukemia (AML) have a different risk of infection when treated with chemotherapy protocols developed for children with DS compared to AML treatment protocols developed for children without DS. Methods. We conducted a retrospective, population-based cohort study that included DS children ≤ 18 years of age with de novo, non-M3 AML diagnosed between January 1995 and December 2004, and treated at 15 Canadian centers. Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle of chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease or death (whichever occurred first). Trained research associates abstracted all information from each site. Results: There were 31 children with DS included; median age was 1.7 (range 0.1-11.1) years. Eleven were treated according to a DS-specific protocol while 20 were treated with non-DS specific protocols. A total of 157 courses of chemotherapy were delivered. Microbiologically documented sterile site infection occurred in 11.9% and 14.3% of DS-specific and non-DS specific AML treatment courses respectively. Sepsis was rare and there were no infection-related deaths. In multiple regression, treatment with a DS-specific protocol was independently associated with a reduction in microbiologically documented sterile site infection (adjusted odds ratio (OR) 0.65, 95% confidence interval (CI) 0.42-0.99; P = 0.044), and clinically documented infection (adjusted OR 0.36, 95% CI 0.14-0.91; P = 0.031) but not bacteremia (adjusted OR 0.73, 95% CI 0.44-1.22; P = 0.231). Conclusions: Our study suggests that children with DS do not experience excessive infectious toxicity during treatment for AML compared to children without DS. Incorporation of DS-specific AML treatment protocols is associated with a more favorable infection profile for children with DS-AML.
UR - http://www.scopus.com/inward/record.url?scp=84888588169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888588169&partnerID=8YFLogxK
U2 - 10.1186/1750-9378-8-47
DO - 10.1186/1750-9378-8-47
M3 - Article
C2 - 24289042
AN - SCOPUS:84888588169
SN - 1750-9378
VL - 8
JO - Infectious Agents and Cancer
JF - Infectious Agents and Cancer
IS - 1
M1 - 47
ER -